Aytu BioPharma(AYTU) - 2024 Q4 - Annual Results

Exhibit 99.1 Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results Full year fiscal 2024 consolidated net revenue of $81.0 million; Rx Segment net revenue of $65.2 million Full year fiscal 2024 ADHD Portfolio net revenue up 23% compared to fiscal 2023 Full year fiscal 2024 adjusted EBITDA1 improved to $9.2 million, up by $5.7 million compared to fiscal 2023 $20.0 million cash balance at June 30, 2024 Company expects Rx Segment net revenue and adjusted EBITDA growt ...